Researchers have developed a deep learning model that can spot longitudinal changes in patients' brain imaging that could be indicative of cancer recurrence.
Michael Reardon, MD, detailed five-year data out of ACC.25 that found Medtronic's Evolut TAVR platform performs as well as SAVR—and even better in some ways.
Reviewing data from more than 6,000 patients, researchers found little evidence of the "obesity paradox" observed elsewhere. Underweight TAVR patients, however, may face some significant long-term risks.
The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels.
India-based Meril Life Sciences has been manufacturing its Myval transcatheter heart valves for years, but the technology has not yet gained FDA approval. This latest head-to-head comparison included data from more than 1,000 TAVR patients.
Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.
It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis.
As a person’s concentration dwindles during resting state or task-based sequences, the resultant brain activity observed on imaging could be misleading.